SHANGHAI, China, March 21, 2019 – Asieris Pharmaceuticals, a clinical-stage biopharmaceutical company, announced today that Dr. Kevin Pan, company’s CEO, and Dr. Ethan Guo, VP of CMC, have been invited to participate in the “Asia Pharma R&D Leaders Summit 2019” , organized by Deliver Life Science and supported by SAPA-GP and Bayhelix, to be held on April.16-17, 2019, at the InterContinental Shanghai Ruijin Hotel, PR China. (Forum Website: www.aprdl2019.com).
Dr. Pan will make a plenary keynote speech with the title of “How to build up China biotech’s leadership in the global development of innovative therapies”. Later, Dr. Pan will join the panel discussion on “Promoting China innovation & strengthening R&D collaboration for next generation therapeutic biologic development in China”. Dr. Guo will be a panel speaker at the “Drug marketing authorization holder (MAH) system in China: CMO – MAH integration collaboration programs”.
The summit aims to provide a platform for executive level interactions and matching between companies and investors for domestic and overseas executives. Over 400 senior pharma R&D executives, CEOs and entrepreneurs will explore together how to advance China derived innovation and strengthen R&D collaboration and partnership.
About Asieris Pharmaceuticals
Asieris Pharmaceuticals is dedicated to becoming a specialty pharmaceutical company focusing on discovery, development and commercialization of innovative therapies to treat genito-urinary diseases. Founded in 2010, Asieris currently has operations in Shanghai, Beijing, Taizhou City of Jiangsu Province, and the United States. Asieris’ strategy is to build a strong pipeline through internal R&D and in-licensing, develop and commercialize products in China and gain access to ex-China markets with global partners.